REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

May 06, 2026 07:05 AM EDT

-- Company will also report first quarter 2026 financial results and operational highlights --

ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast on Thursday, May 14, 2026, at 8:00 a.m. ET to discuss topline results from the pivotal trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy.

The webcast will feature leading Duchenne physicians including Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital, Carolina Tesi-Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children's Health, and Diana Castro, M.D., Board Certified Neurologist and Neuromuscular Physician, Founder and Director Neurology and Neuromuscular Care Center and Founder and Director Neurology Rare Disease Center.

The company will also report financial results and operational highlights for the first quarter ended March 31, 2026 pre-market Thursday, May 14.

The live webcast can be accessed here and in the Investor section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-on-may-14-to-discuss-topline-results-from-pivotal-trial-of-rgx-202-for-duchenne-muscular-dystrophy-302763647.html

SOURCE REGENXBIO Inc.